Clinical Trials
16 trialsNCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT05054725 2026-01-06
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Phase 2 Completed
NCT04564027 2025-08-29
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
AstraZeneca
Phase 2 Completed
NCT03126019 2025-03-14
CITADEL-203
Incyte Corporation
Phase 2 Completed
NCT02861300 2024-12-19
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT03309150 2024-11-29
ATRi Transition Rollover Study
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT05246111 2024-11-22
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT04768296 2024-09-26
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
EMD Serono
Phase 2 Completed
NCT01320085 2024-01-24
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Pfizer
Phase 2 Completed
NCT04285723 2023-02-09
EPIK-P1
Novartis
Completed
NCT01276379 2021-07-02
POSIBA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT01070316 2017-03-13
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed
NCT01449370 2017-03-09
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
Takeda
Phase 1 Completed
NCT01572727 2017-03-09
BELLE-4
Novartis
Phase 2/3 Completed
NCT00790400 2017-02-17
EXIST-2
Novartis
Phase 3 Completed
NCT00411619 2014-10-20
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Completed